TriSalus Life Sciences ( (TLSI) ) has released a notification of late filing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
TriSalus Life Sciences has announced a delay in filing its Form 10-K (Yearly Report) for the financial period ending December 31, 2023, as per the Form 12b-25 notification. The delay is primarily due to the need for additional time and resources to address errors in stock-based compensation and clinical trial expenses, as well as to evaluate newly identified deficiencies in these areas. The company expects to file the delayed report within fifteen calendar days following the prescribed due date. Preliminary financial results indicate a significant increase in revenue and a decrease in net losses compared to the previous year. However, these results are subject to change pending the completion of the company’s financial statements. TriSalus is actively working to resolve these issues, as indicated by the signature of CFO James Young on the notification.
More about TriSalus Life Sciences
YTD Price Performance: 10.44%
Average Trading Volume: 45,507
Technical Sentiment Signal: Hold
Current Market Cap: $167.7M
Find detailed analytics on TLSI stock on TipRanks’ Stock Analysis page.